Evidence map›Paper›PMID 36551102›Full record

ArticleBiosensors2022

Development of a Single-Chain Variable Fragment of CR3022 for a Plasmonic-Based Biosensor Targeting the SARS-CoV-2 Spike Protein.

Taufik Ramdani Tohari, Isa Anshori, Umi Baroroh, Antonius Eko Nugroho, Gilang Gumilar, Shinta Kusumawardani, Sari Syahruni, Brian Yuliarto, Wyanda Arnafia, Irvan Faizal and 3 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Taufik Ramdani TohariResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung 40133, Indonesia.
Isa AnshoriLab-on-Chip Group, Biomedical Engineering Department, Institute of Technology, Bandung 40132, Indonesia.ORCID 0000-0001-5134-7264
Umi BarorohResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung 40133, Indonesia.ORCID 0000-0003-2011-7161
Antonius Eko NugrohoLab-on-Chip Group, Biomedical Engineering Department, Institute of Technology, Bandung 40132, Indonesia.
Gilang GumilarResearch Center for Nanoscience and Nanotechnology (RCNN), Institut Teknologi Bandung, Bandung 40132, Indonesia.ORCID 0000-0002-7955-7965
Shinta KusumawardaniResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung 40133, Indonesia.
Sari SyahruniResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung 40133, Indonesia.
Brian YuliartoResearch Center for Nanoscience and Nanotechnology (RCNN), Institut Teknologi Bandung, Bandung 40132, Indonesia.ORCID 0000-0003-0662-7923
Wyanda ArnafiaResearch and Development Division, PT. Tekad Mandiri Citra, Bandung 40292, Indonesia.
Irvan FaizalCentre for Vaccine and Drug Research, National Research and Innovation Agency Republic of Indonesia, Kawasan Puspiptek Serpong, Tangerang Selatan 15314, Indonesia.
Yeni Wahyuni HartatiResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung 40133, Indonesia.ORCID 0000-0003-1463-6352
Toto SubrotoResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung 40133, Indonesia.
Muhammad YusufResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung 40133, Indonesia.ORCID 0000-0003-1627-1553
Padjadjaran University · IDBandung Institute of Technology · IDAtma Jaya Catholic University of Indonesia · ID

Funding

Ministry of Research, Technology and Higher Education 02/Swakelola/PPK4/BPPT/IV/2020
6 · The paper itself

Abstract

Two years after SARS-CoV-2 caused the first case of COVID-19, we are now in the "new normal" period, where people's activity has bounced back, followed by the easing of travel policy restrictions. The lesson learned is that the wide availability of accurate and rapid testing procedures is crucial to overcome possible outbreaks in the future. Therefore, many laboratories worldwide have been racing to develop a new point-of-care diagnostic test. To aid continuous innovation, we developed a plasmonic-based biosensor designed explicitly for portable Surface Plasmon Resonance (SPR). In this study, we designed a single chain variable fragment (scFv) from the CR3022 antibody with a particular linker that inserted a cysteine residue at the second position. It caused the linker to have a strong affinity to the gold surface through thiol-coupling and possibly become a ready-to-use bioreceptor toward a portable SPR gold chip without purification steps. The theoretical affinity of this scFv on spike protein was -64.7 kcal/mol, computed using the Molecular Mechanics Generalized Born Surface Area (MM/GBSA) method from the 100 ns molecular dynamics trajectory. Furthermore, the scFv was produced in

Indexed as

Biosensing TechniquesCOVID-19Single-Chain AntibodiesAntibodies, MonoclonalAntibodies, NeutralizingHumansSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingCR3022Single-Chain AntibodiesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2molecular dynamicsplasmonic-based bioreceptorportable SPRSARS-CoV-2scFv

Identifiers

PMID36551102
PMCPMC9776105
OpenAlexW4311720295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.